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Abstract Pulmonary aspergillosis is frequently re-
ported in parrots, falcons, and other birds held in
captivity. Inhalation is the main route of infection for
Aspergillus fumigatus, resulting in both acute and
chronic disease conditions. Itraconazole (ITRA) is an
antifungal commonly used in birds, but its administra-
tion requires repeated oral dosing, and the safety margin
is narrow. To investigate the efficacy of inhaled ITRA,
six groups of ten young quails (Coturnix japonica)
were inoculated intratracheally with 5 9 106 spores
(3 groups) or 5 9 107 spores (3 groups). Animals were
exposed to nebulized ITRA nanosuspension as 10 %
suspension or 4 % suspension, once daily for 30 min,
starting 2 h after inoculation for 6 days. Control groups
were exposed to nebulized saline for the same period of
time. Survival and clinical scores were evaluated, and
animals were subjected to gross pathology. In control
animals, aspergillosis resulted in systemic disease
without pulmonary or air sac granulomas. Animals died
from multiple organ failure. Inhalation of 10 % ITRA
nanosuspension blocked lethality and prevented dis-
ease-related symptoms in the quails exposed to the low
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dose of spores, while the disease course in quails
inoculated with the high-spore dose was retarded. Inhala-
tion of 4 % ITRA nanosuspension was less effective.
Both inhalations were well tolerated, and gross pathol-
ogy did not reveal signs of local toxicity. The data indi-
cate that inhaled administration of 10 % ITRA nanosus-
pension is capable of alleviating an acute A. fumigatus
infection in quails. A lower ITRA concentration may be
only active in chronic pulmonary aspergillosis.
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Introduction
Aspergillosis is the most common fungal disease in
birds and is in most cases caused by Aspergillus
fumigatus although other Aspergillus spp. are occa-
sionally involved [2, 7]. Infections caused by A.
fumigatus have been reported in falcons and other
birds of prey [8], parrots [23], and penguins [25] held in
captivity. Pulmonary aspergillosis is frequently found
also in wildlife centers, largely impairing the reha-
bilitation success of birds [1, 25]. Inhalation is
considered the main route of infection for Aspergillus
species in birds [18]. The conidia of A. fumigatus are
much smaller than those of other species of Aspergil-
lus. They are too small to be trapped in the nasal cavity;
this may explain why A. fumigatus is the predominant
species of airborne fungal infections in birds [12, 19].
Treatment of this disease is probably one of the most
challenging tasks of avian practitioners [13]. In recent
years, the azole derivative voriconazole has been
introduced in the treatment of avian aspergillosis [10,
15, 22]. However, as with other azole derivatives, the
oral treatment is hampered by the fact that the safety
margin is narrow and toxicity induced by systemic
administration of azoles is well known, requiring the
careful balancing of administered dose and induced
toxicity [4, 24]. Oral administration requires repeated
fixation, which imposes stress on the birds. Therefore,
alternative treatment regimens are of high interest.
An azole formulation that can be nebulized to
administer the drug in an aerosol by inhalation should
solve many of these issues. Recently, we have described
a nanoparticulate suspension of itraconazole (ITRA),
which can be nebulized using standard pressurized air-
driven devices [20]. The droplet size was independent
of the technology in the respirable size range of 5 lm.
The suspension was proven to be stable upon storage
and could be manufactured with reproducible quality.
The inhaled administration in rats and quails resulted in
high local drug concentration, indicating good deposi-
tion in the respiratory tract, while systemic exposure
was reduced, opening up the chance to reduce the risk
for systemic toxicity [20, 21]. To evaluate whether the
inhaled administration of ITRA nanosuspension can
alleviate the course of experimentally induced
aspergillosis, an intratracheal challenge model in quails
was selected, which had been used previously to
evaluate the antifungal activity of orally administered
voriconazole [24].
Materials and Methods
Animals
Clinically healthy quails (Coturnix japonica) of both
sexes, aged 10 days (25–30 g body weight), were used
for the experiments. Quails of this age were selected,
since juvenile animals are more susceptible to A.
fumigatus infection than adult animals [5, 24]. The
animals were obtained from Didactic Experimental
Station of the University of Life Sciences in Lublin
(Poland) and were housed in groups of 20 in collective
cages at a controlled temperature (26–28 C) and
humidity (50–60 %) under continuous lighting (natural
and artificial). They were fed ad libitum commercial diet
(DKA-Prestarter, Agropol Sp.J., Motycz, Poland). Birds
had free access to fresh water during the experiment. The
experimental protocols were approved by the Ethical
Committee of the Medical University in Lublin (license
number 28/2013). All procedures involving animals and
their care were conducted in accordance with the
European Communities Council Directive of November
24, 1986 (86/609/EEC) and Polish legislation acts
concerning animal experimentation.
Inoculum
Aspergillus fumigatus ATCC 46645 wild-type strain
was used for the experiments. This strain was selected
since it is a standardized strain with reproducible
characteristics and known sensitivity to ITRA.
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Depending on the test system used, the minimal
inhibitory concentration (MIC) of this strain was shown
to be in the range of 0.125–0.5 lg/ml [26].A. fumigatus
ATCC 46645 was grown on malt extract agar. Five-
day-old cultures were washed with 5 ml 0.01 %
polysorbate 80 in phosphate-buffered saline (PBS) to
harvest conidia. The spore suspension was filtered
through a cell strainer (40 lm pore size; BD Bio-
sciences, Germany) and washed three times in 0.01 %
polysorbate 80 in PBS. The number of conidia was
determined using a CASY cell counter (model TT;
Roche Innovatis AG, Germany), and the suspension
was adjusted to a concentration of 109 conidia/ml PBS.
ITRA Nanosuspension
The nanoparticulate ITRA suspension was prepared as
described previously [20]. Briefly, a wet-milling pro-
cess using a pearl mill (VMA Getzmann, Reichshof,
Germany) with organic grinding beads was used.
Microcrystalline pure ITRA drug powder (Matrix
Laboratories Ltd, Secunderabad, India) was suspended
in distilled water at a concentration of 10 % by weight,
with the addition of polysorbate 80 at 1.4 % using a
high shear mixer (Ultra-Turrax homogenizer, IKA-
Werke GmbH & Co, Staufen, Germany). The suspen-
sion was milled for 4 h. The resulting suspension had a
mean particle size of 180–230 nm with a narrow
particle size distribution and was found to be stable
upon storage at 8 C for at least 9 months. To generate
a suspension containing 4 % ITRA, 10 ml of the 10 %
suspension was mixed with 15 ml of a 1.4 % polysor-
bate 80 solution in water using a magnetic stirrer. Upon
release testing, the particle size distribution of ITRA
particles was found to be in the range of 180–230 nm
with narrow particle size distribution, and the suspen-
sion could be nebulized with droplet size in the range of
less than 5 lm using Pariboy SX with PARI LC Sprint
nebulizer equipped with red insert for fine droplets (Pari
GmbH, Starnberg, Germany).
Statistical Analysis
The survival data are displayed as Kaplan–Meier
survival plot. The statistical analysis of survival
differences between groups was done with a log-rank
test. All infected birds were included. Cumulative
disease scores were plotted as group sum data. The
statistical analysis of the disease scores was based on
the area under the disease score plot for the treatment
compared to vehicle treatment, using the Chi-square
test with a-adjustment for multiple comparisons.
Pilot Experiment to Identify the Optimal
Inoculation Dose
To identify the optimal inoculation dose, three groups
of 10 male 10-day-old quails were administered
5 9 105, 5 9 106, or 5 9 107 conidia intratracheally.
For instillation, each animal was taken in one hand.
The beak was opened, and using a small animal 26G
intravenous catheter with the stylet removed attached
to a 1-ml syringe filled with 0.1 ml suspension, the
suspension was administered directly and deep into
the trachea as bolus. Animals were held for 10 s after
the instillation with the head up to prevent reflow of
the suspension. Thereafter animals were returned to
the observation cages. Ten uninfected control birds
were intratracheally instilled with 0.1 ml of polysor-
bate 80 (0.05 % vol/vol) in saline.
Following administration, the birds were observed
once daily for 9 days (day of instillation = day 1) for
behavioral signs of disease and for mortality. The study
duration was selected based on the disease course,
resulting in spontaneous recovery of surviving animals
within less than 2 weeks and no deaths after day 7 [24]. A
composite disease score was constructed from the
following observation parameters: general signs of
disease/discomfort (0 absent, 1 equivocal, 2 present),
somnolence (0 absent, 1 equivocal, 2 present), respiratory
impairment (0 absent, 1 open beak, 2 open beak ? tail
co-movement), survival (0 alive, 8 death). Each pa-
rameter was determined once daily. In the case of death,
the value of 8 was carried forward. In addition to the
disease score, the mortality was evaluated separately. The
body weight was recorded on days 1, 4, 6, and 8 during the
study. Gross pathology was conducted on each animal
which died and on the remaining animals on day 9.
The inoculation with 5 9 105 conidia did not result
in a clinically manifest disease. With the exception of
one animal with possible mild symptoms of disease,
starting on day 5, no symptoms were recorded. In
contrast, the administration of either 5 9 106 or
5 9 107 conidia resulted in a fulminant disease
development with first signs of disease becoming
visible on the day following inoculation. The disease
development was somewhat protracted with 5 9 106
conidia, but the difference was small. In both groups,
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the lethality reached 4 of 10 animals on day 9 (Fig. 1a,
b). The A. fumigatus inoculation had no consistent
effect on the group mean body weight development.
Gross pathology revealed unspecific signs of cardio-
vascular failure including lung hyperemia, but no
fungal granulomas and no macroscopically visible
fungal growth were seen on the air sac surfaces, in line
with the acute course of the disease (data not shown).
Treatment Regimens
Due to the similarity in disease development following
inoculation of 5 9 106 and 5 9 107 conidia, it was
decided to evaluate the pharmacological effect of
inhaled ITRA nanosuspension in both quails inoculat-
ed with 5 9 106 conidia (low inoculation groups) and
5 9 107 conidia (high inoculation groups). Two
groups of 30 quails each were inoculated either with
5 9 106 or 5 9 107 conidia. The animals of each
group were randomized to three treatment groups of
ten quails each, to be treated with 10 % suspension,
4 % suspension, or vehicle. Starting 2 h after the
inoculation, the animals were put in an inhalation cage
and were exposed to nebulized ITRA nanosuspension
for 30 min, as described previously [21]. In brief, a
polycarbonate Eurostandard type III rodent cage
(bottom area 390 9 230 mm, height 150 mm, total
volume *13.5 l) was equipped with a tightly sealing
custom-made acrylic glass cover with an inlet in the
left front corner (18 mm diameter) and a tubing outlet
in the right rear corner (18 mm diameter) to allow for a
diagonal airflow through the chamber. The inlet was
connected directly with a short section of silicone
tubing (25 cm long, 18 mm diameter) to a pressurized
air nebulizer (Pari Boy SX with PARI LC Sprint
nebulizer equipped with red insert for fine droplets
(Pari GmbH, Starnberg, Germany). To prevent quail
from hiding in corners or blocking the inlet or outlet to
enable a homogenous drug inhalation, the cage was
equipped with a circular plastic mesh sized to block
the corners and to protect the inlet and outlet. All 10
quails of each group were placed in the cage for
simultaneous exposure. The inhalation procedure was
conducted once daily in the late morning for six
consecutive days. The animals were observed for the
development of the disease using the composite
disease score and for mortality once daily starting
the day of inhalation. In addition, the body weight
development was recorded on days 1, 4, and 8. Gross
pathology was conducted on each animal which died
and on the remaining animals on day 8.
Results
ITRA nanosuspension could be easily nebulized using
Pariboy SX with PARI LC Sprint nebulizer equipped
with red insert for fine droplets (Pari GmbH, Starn-
berg, Germany). Within 30 min of nebulization, a
volume of about 4.5 ml of suspension could be
successfully nebulized. Based on this nebulization
capacity and the air flow generated by Pariboy SX, the
Fig. 1 Kaplan–Meier survival curve (a) and cumulative
disease score (b) of groups of quails inoculated intratracheally
with 5 9 105, 5 9 106, or 5 9 107 spores of A. fumigatus
(n = 10/group). The log-rank test revealed that the inoculation
with 5 9 106 or 5 9 107 spores significantly reduced survival
(p = 0.02). A cumulative disease score was generated by adding
up all scores of all animals on the respective day. For statistical
analysis of the resulting group disease score, the area under the
score curve (AUC) was calculated and compared using the Chi-
square test with a-adjustment for multiple comparisons (insert-
ed table)
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concentration of ITRA per ml air amounted to 3 lg/ml
air for the 10 % suspension. The administered dose
cannot be easily calculated from these values, since
the respiratory frequency and the respiratory volume
of 10-day-old quails are not known. The inhalation
was well tolerated, and no visible signs of adverse
effects were observed in the quails exposed to
nebulized ITRA from a 4 or 10 % nanosuspension.
In quails inoculated with the lower dose of 5 9 106
conidia, the disease development in the vehicle-
treated group was comparable to the disease develop-
ment in the pilot experiment. On day 8, 2 animals had
died and 3 others had obvious symptoms of disease,
which were pronounced in one of the 3 animals. Gross
pathology of animals which had died revealed un-
specific signs of multiple organ failure including lung
congestion, reddish discoloration of the kidneys, and
liver discoloration and swelling. No specific signs of
fungal infections of the lungs or air sacs were seen. In
animals which had survived until day 8, either no
findings or minimal findings presenting as few
discolored spots in the lung parenchyma were record-
ed. Air sacs were free of fungal deposits or granulo-
mas. Once daily treatment with nebulized ITRA
nanosuspension for 30 min at a concentration of
10 % resulted in a complete protection of the animals
from aspergillosis development. Gross pathology on
day 8 of all animals of the treatment group revealed
normal air sac membranes and lungs. Neither fungal
deposits or granulomas nor treatment-related changes
were seen, paralleling the findings in the vehicle-
treated animals. With the exception of one animal,
which experience equivocal signs of disease on days 5
and 6 only, no other symptoms were recorded. While
in the treated group all animals survived, the log-rank
test failed to show significance, since in the vehicle
group only 2 out of 10 animals had died. However, on
the level of the disease score, the treatment effect was
significant (p\ 0.001). The quails exposed to 10 %
ITRA gained more weight as the quails exposed to
vehicle or 4 % ITRA (data not shown). In the 4 %
ITRA group, a tendency toward retarded development
of symptoms and lethality was observed, but on day 7
following termination of treatment two affected quails
died resulting in an even higher lethality in this group.
The disease score paralleled the survival curve, and
both, the survival and the disease score development,
were not significantly different from the control group
(Fig. 2a, b).
In quails inoculated with the high dose of 5 9 107
conidia, the disease development was more rapid and
more pronounced as compared to the low-conidia
control group. First disease symptoms were seen as
early as on day 2 following inoculation. A first lethality
was seen on day 3, and by day 5, 50 % of animals had
died. No further lethality was observed thereafter. The
disease score again paralleled the survival curve
reaching its maximum on day 6. Gross pathology of
animals which had died revealed again unspecific signs
of multiple organ failure. No specific signs of fungal
infections of the lungs or air sacs were seen. In animals
which had survived until day 8, again either no findings
or minimal findings representing as few discolored
Fig. 2 Kaplan–Meier survival curve (a) and cumulative
disease score (b) of groups of quails inoculated intratracheally
with 5 9 106 spores of A. fumigatus, treated with nebulized
ITRA nanosuspension at a concentration of 4 or 10 %
(n = 10/group). A cumulative disease score was generated by
adding up all scores of all animals on the respective day. For
statistical analysis of the resulting group disease score, the area
under the score curve (AUC) was calculated and compared
using the Chi-square test with a-adjustment for multiple
comparisons (inserted table)
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spots in the lung parenchyma were made. Air sacs were
free of fungal deposits or granulomas.
The treatment with ITRA nanosuspension (4 and
10 % suspension) resulted in a retarded disease
development. While the treatment effect was found
to be highly significant for the disease score develop-
ment for both treatment groups, the improvement in
survival was small and did not reach the level of
significance. With both treatments, no complete
protection from lethality was obtained. No clear dose
response for the survival could be observed, but there
was a tendency that the disease score was lower in the
10 % group as compared to the 4 % group (Fig. 3a, b).
Gross pathology of animals which had died and in
those which had survived until day 8 was not different
from vehicle-treated animals.
Discussion
Pulmonary aspergillosis is caused by inhalation of
spores of Aspergillus species. A clinically manifest
infection occurs only under certain circumstances,
such as a very high exposure with spores, or if the
bird has an impaired immune system, i.e., if the
innate defense mechanisms do not succeed in
eliminating the infection [18]. While in rodent
models of pulmonary aspergillosis, an immune
suppression is required to enable pulmonary infection
[16], juvenile but not adult pigeons, and juvenile
quails can be infected in the absence of systemic
immune suppression [5, 24]. For the present study,
we selected 10-day-old quails as model species, since
it had been shown previously, that in quails of this
age, the intratracheal instillation of A. fumigatus
spore suspension induced a pulmonary aspergillosis
with high pulmonary burden of A. fumigatus, leading
to clinically manifest disease and mortality within up
to 10 days, with subsequent complete recovery in
surviving animals [24]. While pulmonary aspergillo-
sis was verified by measuring colony-forming units
per gram lung parenchyma, fungal granulomas were
seen only in two out of 60 quails inoculated.
Pathological findings were in line with systemic
mycosis as primary cause of death, and systemic
voriconazole treatment, while resulting in increased
survival, had little effect on the pulmonary pathology
in this study [24]. In our pre-study, we could verify
that an intratracheal inoculation of 5 9 106 A.
fumigatus spores is adequate to induce a clinically
manifest disease in [50 % of inoculated quails,
resulting in modest mortality. An inoculation with a
tenfold higher dose of spores resulted in a more rapid
development of the disease symptoms, but again not
all animals inoculated developed active disease
(Fig. 1). Gross pathology failed to demonstrate lung
selective aspergillosis, and no fungal lawn or
granulomas were induced, as reported previously
for this model [24]. It was decided to evaluate the
treatment effect of inhaled ITRA in quails inoculated
with both 5 9 106 and 5 9 107 spores per animal.
The mortality rate in the 5 9 106 spores group was
comparable to previously published data [24].
Although inhalational administration is well estab-
lished as a treatment option for humans, little is known
about this application form in birds. Nebulization of
drugs is occasionally used for vaccination or for drug
Fig. 3 Kaplan–Meier survival curve (a) and cumulative
disease score (b) of groups of quails inoculated intratracheally
with 5 9 107 spores of A. fumigatus (n = 10/group). A
cumulative disease score was generated by adding up all scores
of all animals on the respective day. For statistical analysis of the
resulting group disease score, the area under the score curve
(AUC) was calculated and compared using the Chi-square test
with a-adjustment for multiple comparisons (inserted table)
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administration [9, 17], but data on treatment of
pulmonary aspergillosis using the inhalation route
are limited to few case studies [7]. We have previously
shown that a stable nanosuspension of ITRA can be
generated and successfully nebulized with pressurized
air nebulizers [20]. Single and repeated inhalations in
rats and quails were well tolerated and resulted in high
and persistent lung tissue concentrations, while the
plasma exposure was very low [20, 21]. In gray parrots
and falcons, the inhalation procedure could be con-
ducted without inducing stress by covering a small
cage with a transparent tight cover and nebulizing this
chamber (Rundfeldt et al., unpublished observation).
This opened up the option that ITRA inhalation could
be a targeted treatment option of lung aspergillosis,
preventing the systemic toxicity of azole derivatives,
which normally requires a careful balancing of dose
and adverse effects [3], while at the same time
omitting the stress associated with oral treatment. In
the present study, we could show that once daily
inhalation of a nebulized 10 % nanosuspension of
ITRA could completely block the development of
aspergillosis in quails following inoculation of
5 9 106 A. fumigatus spores, and this treatment
regimen was well tolerated. No treatment-related
symptoms were observed, and the dissection of the
surviving animals on day 8 revealed no macroscopic
abnormalities. The pharmacological activity of the
10 % suspension is comparable to results obtained
following once daily oral administration of 40 mg/kg
voriconazole in the same model, while the activity of
20 mg/kg voriconazole had little pharmacological
effect, comparable to the inhalation of 4 % ITRA
nanosuspension. However, a dose of 20 mg/kg
voriconazole administered once daily was shown to
result in mild histological as well as macroscopic liver
abnormalities in pigeons [3], indicating that a dose of
40 mg/kg is already in the toxic dose range. If the
spore inoculation was increased to 5 9 106 spores,
both the 4 and 10 % suspension was only capable of
retarding the disease development, but the lethality
could not be prevented. Our pharmacokinetic studies
in quails following inhalation of 1 and 10 % indicated
that repeated inhalation of the 10 % suspension
resulted in an ITRA lung tissue concentration of well
above 50 lg/g lung tissue which was maintained for
more than 72 h following the last dose. This tissue
concentration is more than 100-fold above the MIC of
ITRA for A. fumigatus of about 0.5 lg/ml [6]. From
these data, we had expected that the 4 % inhalation
would have been similarly effective as compared to
the 10 % inhalation. However, this was not the case. A
possible explanation may be that the inhaled ITRA
nanoparticles are dissolving very slowly on the lung
surfaces. Crystalline ITRA, even if sized at 250 nm,
cannot be pharmacologically active, but only the
fraction dissolved can contribute to the suppression of
growth of A. fumigatus. One possibility to estimate the
dissolved fraction is the measurement of the primary
active metabolite, hydroxyl-itraconazole (OH-ITRA).
Following inhaled administration of 10 % ITRA
nanosuspension for 5 days, the tissue concentration
of OH-ITRA was found to be in the range of 1 lg/g
lung tissue, and this concentration was maintained for
72 h following the last dose [21]. These data indicate
that ITRA nanoparticles accumulate in lung tissue and
are slowly dissolved to be metabolized in the lung
tissue. A reduction in the concentration of ITRA
nanosuspension from 10 to 4 % results in reduced
deposition of ITRA and hence in reduced availability
for dissolution and metabolization to form OH-ITRA.
In fact, following single-dose inhalation of a 1 %
suspension, the lung tissue concentration of OH-ITRA
did by far not reach the MIC of A. fumigatus of 0.5 lg/
ml [21].
From these data, we can conclude that once daily
30-min inhalation of a 10 % ITRA nanosuspension is
required to obtain active tissue concentrations of
ITRA and OH-ITRA for the treatment of pulmonary
aspergillosis in birds. Having to administer the 10 %
suspension, the advantage of local treatment of the
lungs without exposing the systemic circulation to
ITRA is not achieved, since at this concentration
circulating plasma levels of both ITRA and OH-ITRA
were found [21]. Nevertheless, the model of intratra-
cheal inoculation of a high load of A. fumigatus spores
is rather a model of acute than of chronic aspergillosis.
In fact, no granuloma formation on air sac membranes
and no fungal deposits on the serosae were visible,
indicating that the course of the disease is rather acute,
presumably with systemic aspergillosis contributing to
the unspecific signs of death observed in our study. A
hematological spread of pulmonary aspergillosis has
been described previously [11, 14]. In chronic nonin-
vasive pulmonary aspergillosis, a lower drug concen-
tration may be also active. However, this can be only
evaluated in a clinical setting in affected birds. Studies
in gray parrots and in falcons will have to be conducted
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to evaluate whether a 10 % or a 4 % suspension can be
safely inhaled in these species and whether manifest
aspergillosis can be successfully treated.
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